Seungil Han

Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design

Leonard Buckbinder, Daniel P. Walker, L. Buckbinder, 2009, Journal of Biological Chemistry.

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.

Li Xing, Leonard Buckbinder, Amy Baumann, 2009, Bioorganic & medicinal chemistry letters.

Tetrameric Architecture of the Circadian Clock Protein KaiB

Kenichi Hitomi, E. Getzoff, T. Oyama, 2005, Journal of Biological Chemistry.

Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.

Dennis E Danley, P. Lemotte, M. Mansour, 2005, Journal of medicinal chemistry.

Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.

Allan Wissner, Nicole Caspers, R. Kurumbail, 2011, Bioorganic & medicinal chemistry letters.

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.

Leonard Buckbinder, Jacquelyn Klug-McLeod, Angel Guzman-Perez, 2008, Bioorganic & medicinal chemistry letters.

Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free‐Energy Perturbation (FEP)

Atli Thorarensen, Joseph McDonald, A. Moretto, 2016, ChemMedChem.

Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa

J Richard Miller, Veerabahu Shanmugasundaram, V. Shanmugasundaram, 2010, Proceedings of the National Academy of Sciences.